Avricore Health Inc.
Avricore Health Inc. is a healthcare-focused company engaged in enhancing patient care through technology and data-driven solutions. Primarily, this company specializes in providing point-of-care technologies that aim to connect healthcare professionals with critical diagnostic data in real time. Their flagship product, the HealthTab platform, offers a unique solution by delivering rapid diagnostic test results outside of traditional laboratory settings. This service has significant applications in pharmacies and clinics, enabling more efficient and accessible healthcare services. Avricore Health Inc.'s work is pivotal in the ongoing transformation of the healthcare industry, particularly in increasing the accessibility and timeliness of medical diagnostics. By integrating cutting-edge technology with healthcare services, the company plays a crucial role in advancing patient-centric care. This focus on innovative healthcare solutions situates Avricore Health Inc. at the forefront of modern healthcare, addressing both current analytical demands and future-oriented healthcare visions.
$0.00
+$0.00 (+0.00%)
Price from 3 days ago
The business is unprofitable at the operating level (-237.21% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 88.8% YoY. Margins deteriorated 240.1pp alongside, both lines moving the wrong way.
Free cash flow declined 213% versus the prior year, cash generation momentum has weakened. ROIC dropped from 5.48% to -84.88%, capital efficiency is deteriorating.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
C$144K
▼ -88.8% YoY
Net Income (TTM)
-C$2M
▼ -177.8% YoY
Op. Margin
-993.96%
▼ -240.1pp YoY
ROIC
-84.88%
▼ -90.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-C$1M
▼ -213.1% YoY
Op. Cash Flow (TTM)
-C$1M
▼ -180.6% YoY
Net Debt
-C$238K
Net Cash Position
Cash & Equiv.
C$238K
3Y CAGR: -32.9%
Continue Research
Is Avricore Health (AVCRF) overvalued?
Avricore Health (AVCRF)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Avricore Health scores 20/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from company filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
Is Avricore Health a high-quality business?+
Avricore Health scores 20 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -994.0% operating margin and a -84.9% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from company filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is Avricore Health a good stock to buy right now?+
That depends on valuation and quality together, not either alone. you should weigh AVCRF's valuation and scores 20/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from company filings, not investment advice.
Related stocks: Diagnostics & Research
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.